FHTX RSI Chart
Last 7 days
-0.5%
Last 30 days
-4.3%
Last 90 days
-15.2%
Trailing 12 Months
-15.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 33.9M | 0 | 0 | 0 |
2023 | 20.6M | 21.7M | 32.6M | 34.2M |
2022 | 5.0M | 9.2M | 15.8M | 19.2M |
2021 | 652.3K | 874.5K | 1.1M | 1.3M |
2020 | 0 | 0 | 0 | 430.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 11, 2024 | cavalie fanny | sold | -72,133 | 6.5576 | -11,000 | chief strategy/bus ops officer |
Aug 17, 2023 | gottschalk adrian | gifted | - | - | -63,000 | chief executive officer |
Aug 17, 2023 | gottschalk adrian | gifted | - | - | 63,000 | chief executive officer |
Aug 16, 2023 | agresta samuel | acquired | 1,158,020 | 3.72 | 311,297 | chief medical officer |
Aug 16, 2023 | agresta samuel | sold | -2,568,200 | 8.25 | -311,297 | chief medical officer |
May 26, 2023 | gottschalk adrian | gifted | - | - | -300,000 | chief executive officer |
Feb 17, 2023 | gottschalk adrian | gifted | - | - | -4,371 | chief executive officer |
Feb 17, 2023 | gottschalk adrian | gifted | - | - | 4,371 | chief executive officer |
Feb 17, 2023 | gottschalk adrian | sold | - | - | -184,939 | chief executive officer |
Oct 25, 2022 | gottschalk adrian | acquired | - | - | 4,371 | chief executive officer |
Which funds bought or sold FHTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | Colony Group, LLC | new | - | 632,000 | 632,000 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -82,889 | - | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.91 | -7,867 | 13,715 | -% |
May 15, 2024 | JACOBS LEVY EQUITY MANAGEMENT, INC | added | 101 | 757,346 | 1,451,170 | 0.01% |
May 15, 2024 | HSBC HOLDINGS PLC | added | 16.21 | 15,462 | 105,958 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -56.22 | -102,114 | 85,406 | -% |
May 15, 2024 | BARCLAYS PLC | reduced | -41.52 | -83,000 | 129,000 | -% |
May 15, 2024 | Euclidean Capital LLC | unchanged | - | 409,178 | 10,559,900 | 1.35% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -74.2 | -7,205 | 2,644 | -% |
May 15, 2024 | Sio Capital Management, LLC | unchanged | - | 31,635 | 816,419 | 0.24% |
Unveiling Foghorn Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Foghorn Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Foghorn Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 |
Revenue | -12.5% | 5,050,000 | 5,769,000 | 17,478,000 | 5,599,000 | 5,309,000 | 4,184,000 | 6,634,000 | 4,490,000 | 3,920,000 | 713,000 | 41,000 | 279,000 | 286,000 | 232,500 | 179,000 |
Operating Expenses | 6.5% | 33,244,000 | 31,227,000 | 34,559,000 | 37,649,000 | 38,626,000 | 36,070,000 | 34,893,000 | 33,678,000 | 31,724,000 | 28,795,000 | 26,302,000 | 23,540,000 | 23,416,000 | 21,030,000 | 18,668,000 |
S&GA Expenses | -100.0% | - | 7,022,000 | 8,308,000 | 8,401,000 | 8,641,000 | 7,862,000 | 7,965,000 | 7,704,000 | 7,216,000 | 6,332,000 | 5,808,000 | 4,898,000 | 4,690,000 | 4,559,000 | 2,555,000 |
R&D Expenses | 5.5% | 25,534,000 | 24,205,000 | 26,251,000 | 29,248,000 | 29,985,000 | 28,208,000 | 26,928,000 | 25,974,000 | 24,508,000 | 22,463,000 | 20,494,000 | 18,642,000 | 18,726,000 | 16,471,000 | 16,113,000 |
EBITDA Margin | 4.8% | -2.43 | -2.55 | -3.00 | -5.05 | -5.26 | -5.49 | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | 236,000 | 499,000 | 495,000 | 486,000 | 321,000 | 202,000 |
Income Taxes | -100.0% | - | 1,981,000 | 738,000 | 900,000 | 600,000 | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | -13.1% | -25,016,000 | -22,120,000 | -13,607,000 | -28,545,000 | -29,928,000 | -28,886,000 | -25,769,000 | -27,313,000 | -26,914,000 | - | - | - | - | - | - |
EBT Margin | 4.5% | -2.63 | -2.76 | -3.10 | -5.21 | -5.43 | -5.66 | - | - | - | - | - | - | - | - | - |
Net Income | -3.8% | -25,016,000 | -24,106,000 | -14,345,000 | -29,487,000 | -30,488,000 | -28,886,000 | -25,769,000 | -27,313,000 | -26,914,000 | -29,143,000 | -26,080,000 | -23,111,000 | -22,986,000 | -20,758,000 | -18,367,000 |
Net Income Margin | 4.8% | -2.74 | -2.88 | -3.17 | -5.28 | -5.45 | -5.66 | -6.93 | -11.94 | -21.25 | -76.82 | -84.74 | -97.45 | - | - | - |
Free Cashflow | -6.8% | -29,446,000 | -27,578,000 | -27,292,000 | -32,644,000 | -31,816,000 | -29,193,000 | -20,316,000 | -29,376,000 | 271,287,000 | 11,802,000 | -20,732,000 | -19,692,000 | - | - | - |
Balance Sheet | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Assets | -10.8% | 255 | 286 | 313 | 340 | 373 | 405 | 434 | 457 | 488 | 520 | 186 | 209 | 230 | 256 | 142 | 22.00 |
Current Assets | -11.9% | 212 | 240 | 265 | 290 | 321 | 351 | 378 | 400 | 430 | 460 | 124 | 145 | 165 | 191 | 78.00 | 17.00 |
Cash Equivalents | 0.8% | 81.00 | 80.00 | 70.00 | 58.00 | 51.00 | 52.00 | 88.00 | 61.00 | 214 | 103 | 58.00 | 125 | 66.00 | 95.00 | 75.00 | 17.00 |
Liabilities | -2.9% | 352 | 363 | 371 | 389 | 397 | 405 | 410 | 409 | 416 | 423 | 105 | 104 | 105 | 109 | 99.00 | 24.00 |
Current Liabilities | -10.9% | 52.00 | 58.00 | 52.00 | 57.00 | 56.00 | 55.00 | 55.00 | 48.00 | 48.00 | 49.00 | 19.00 | 16.00 | 16.00 | 19.00 | 21.00 | 13.00 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | 20.00 | 20.00 | 20.00 | 20.00 | 9.00 | 11.00 |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.00 | 9.00 | 11.00 |
Shareholder's Equity | -26.3% | -97.49 | -77.19 | - | - | -24.59 | 0.00 | 24.00 | 48.00 | 72.00 | 97.00 | 81.00 | 104 | 125 | 146 | - | - |
Retained Earnings | -5.3% | -496 | -471 | -447 | -433 | -403 | -373 | -344 | -318 | -291 | -264 | -235 | -209 | -185 | -162 | -142 | -94.14 |
Additional Paid-In Capital | 1.1% | 400 | 395 | 392 | 386 | 382 | 377 | 373 | 369 | 365 | 361 | 316 | 313 | 311 | 309 | 9.00 | 6.00 |
Shares Outstanding | 0.7% | 43.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 41.00 | 41.00 | 37.00 | 37.00 | - | - | - | - |
Float | - | - | - | - | 200 | - | - | - | 335 | - | - | - | 209 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 |
Cashflow From Operations | -6.6% | -29,345 | -27,541 | -27,210 | -32,175 | -31,180 | -28,924 | -19,986 | -29,012 | 271,534 | 11,882 | -20,502 | -18,483 | -23,147 | -10,655 | 2,726 | -12,595 | -10,762 | - | - |
Share Based Compensation | 5.7% | 3,224 | 3,051 | 4,094 | 4,470 | 4,572 | 3,781 | 3,802 | 3,509 | 3,244 | - | 2,370 | 2,042 | 1,888 | 1,078 | 877 | 489 | 517 | - | 443 |
Cashflow From Investing | -27.5% | 27,095 | 37,385 | 38,426 | 39,134 | 29,505 | -6,507 | 46,051 | -124,457 | -159,409 | 9,673 | -47,328 | 77,089 | -3,261 | -100,220 | -5,425 | -2,248 | -1,021 | - | - |
Cashflow From Financing | 527.4% | 1,167 | 186 | 1,387 | 103 | 102 | 16.00 | 333 | 1,030 | 384 | 21,740 | 505 | 111 | 62.00 | 128,509 | 40,754 | 47,963 | 247 | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Collaboration revenue | $ 5,050 | $ 5,309 |
Operating expenses: | ||
Research and development | 25,534 | 29,985 |
General and administrative | 7,710 | 8,641 |
Total operating expenses | 33,244 | 38,626 |
Loss from operations | (28,194) | (33,317) |
Other income, net: | ||
Interest income | 2,439 | 2,669 |
Other income, net | 739 | 720 |
Total other income, net | 3,178 | 3,389 |
Loss before income taxes | (25,016) | (29,928) |
Provision for income taxes | 0 | (560) |
Net loss | $ (25,016) | $ (30,488) |
Net loss per share attributable to common stockholders—basic (in dollars per share) | $ (0.59) | $ (0.73) |
Net loss per share attributable to common stockholders—diluted (in dollars per share) | $ (0.59) | $ (0.73) |
Weighted average common shares outstanding—basic (in shares) | 42,428,813 | 41,811,087 |
Weighted average common shares outstanding—diluted (in shares) | 42,428,813 | 41,811,087 |
Comprehensive loss: | ||
Net loss | $ (25,016) | $ (30,488) |
Other comprehensive gain: | ||
Unrealized gains on marketable securities | 329 | 1,116 |
Total other comprehensive gain | 329 | 1,116 |
Total comprehensive loss | $ (24,687) | $ (29,372) |
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | Collaboration Revenue [Member] | Collaboration Revenue [Member] |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 79,253 | $ 80,336 |
Marketable securities | 127,408 | 153,721 |
Prepaid expenses and other current assets | 4,859 | 6,124 |
Total current assets | 211,520 | 240,181 |
Property and equipment, net | 12,187 | 12,956 |
Restricted cash | 1,708 | 1,708 |
Other assets | 1,052 | 1,115 |
Operating lease right-of-use assets | 28,537 | 29,956 |
Total assets | 255,004 | 285,916 |
Current liabilities: | ||
Accounts payable | 5,631 | 6,260 |
Accrued expenses and other current liabilities | 6,265 | 9,108 |
Operating lease liabilities | 8,668 | 8,518 |
Deferred revenue | 31,501 | 34,550 |
Total current liabilities | 52,065 | 58,436 |
Operating lease liabilities, net of current portion | 34,311 | 36,555 |
Deferred revenue, net of current portion | 266,114 | 268,115 |
Total liabilities | 352,490 | 363,106 |
Commitments and contingencies (Note 9) | ||
Stockholders’ deficit: | ||
Preferred stock, $0.0001 par value; 25,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.0001 par value; 175,000,000 shares authorized at March 31, 2024 and December 31, 2023; 42,585,616 shares issued and outstanding at March 31, 2024 and 42,282,040 shares issued and outstanding at December 31, 2023 | 4 | 4 |
Additional paid-in capital | 399,587 | 395,196 |
Accumulated other comprehensive loss | (497) | (826) |
Accumulated deficit | (496,580) | (471,564) |
Total stockholders’ deficit | (97,486) | (77,190) |
Total liabilities and stockholders’ deficit | $ 255,004 | $ 285,916 |